LLY
986.45
+0.17%↑
JNJ
242.9
+0.54%↑
ABBV
221.34
+0.76%↑
NVS
154.3
+0.79%↑
AZN
191.97
+0.98%↑
LLY
986.45
+0.17%↑
JNJ
242.9
+0.54%↑
ABBV
221.34
+0.76%↑
NVS
154.3
+0.79%↑
AZN
191.97
+0.98%↑
LLY
986.45
+0.17%↑
JNJ
242.9
+0.54%↑
ABBV
221.34
+0.76%↑
NVS
154.3
+0.79%↑
AZN
191.97
+0.98%↑
LLY
986.45
+0.17%↑
JNJ
242.9
+0.54%↑
ABBV
221.34
+0.76%↑
NVS
154.3
+0.79%↑
AZN
191.97
+0.98%↑
LLY
986.45
+0.17%↑
JNJ
242.9
+0.54%↑
ABBV
221.34
+0.76%↑
NVS
154.3
+0.79%↑
AZN
191.97
+0.98%↑
24h
Current
Min
71.31
Max
74.33
Income | 6.1M -36M |
|---|---|
Sales | 615K 12M |
EPS | -1.87 |
Profit margin | -301.289 |
Employees | 61 |
EBITDA | 6.9M -29M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +72.67% upside |
Next Earnings | 7 maj 2026 |
|---|
Market Cap | 795M 1.9B |
|---|---|
Previous open | 73.97 |
Previous close | 73.78 |
By Trading Central
Confidence
Strong Bearish Evidence
0.5949 / 0.7406 Support & Resistance
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
16 mar 2026, 21:37 UTC
Lensar and Alcon Agree to Terminate Merger
DJ
Read
16 mar 2026, 19:06 UTC
Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS
DJ
Read
16 mar 2026, 17:44 UTC
Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences
DJ
Read
16 mar 2026, 23:46 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
Read
16 mar 2026, 23:46 UTC
Nikkei May Rise After Oil Prices Decline -- Market Talk
DJ
Read
16 mar 2026, 23:37 UTC
Gold Edges Higher on Possible Technical Recovery -- Market Talk
DJ
Read
16 mar 2026, 23:05 UTC
Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk
DJ
Read
16 mar 2026, 21:56 UTC
DUG Technology's Stock Fall Creates Opportunity -- Market Talk
DJ
Read
16 mar 2026, 21:41 UTC
Global Equities Roundup: Market Talk
DJ
Read
16 mar 2026, 21:41 UTC
Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk
DJ
Read
16 mar 2026, 20:59 UTC
Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition
DJ
Read
16 mar 2026, 20:59 UTC
Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further
DJ
Read
16 mar 2026, 20:59 UTC
Alcon Entered Agreement With LENSAR to Terminate Merger Agreement
DJ
Read
16 mar 2026, 20:57 UTC
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
DJ
Read
16 mar 2026, 20:51 UTC
Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ
DJ
Read
16 mar 2026, 20:50 UTC
Financial Services Roundup: Market Talk
DJ
Read
16 mar 2026, 20:50 UTC
Energy & Utilities Roundup: Market Talk
DJ
Read
16 mar 2026, 20:50 UTC
Basic Materials Roundup: Market Talk
DJ
Read
16 mar 2026, 20:50 UTC
Health Care Roundup: Market Talk
DJ
Read
16 mar 2026, 19:53 UTC
U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ
DJ
Read
16 mar 2026, 19:43 UTC
Global Equities Roundup: Market Talk
DJ
Read
16 mar 2026, 19:43 UTC
Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk
DJ
Read
16 mar 2026, 19:37 UTC
Natural Gas Follows Oil Prices Lower -- Market Talk
DJ
Read
16 mar 2026, 19:20 UTC
Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ
DJ
Read
16 mar 2026, 19:17 UTC
Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk
DJ
Read
16 mar 2026, 19:00 UTC
Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk
DJ
Read
16 mar 2026, 18:23 UTC
LME Restarts Trading After Outage -- Market Talk
DJ
Read
16 mar 2026, 17:36 UTC
Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com
DJ
Read
16 mar 2026, 17:19 UTC
Grains Sink as Investors Steer Toward Equities -- Market Talk
DJ
Read
16 mar 2026, 17:14 UTC
Trump Ends News Conference
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 126.48 USD 72.67%
High 165 USD
Low 70.36 USD
Based on 7 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Strong Bearish Evidence
All events are bearish.
Long Term
Bearish Evidence
All events are bearish.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$